116 results
Page 4 of 6
6-K
ro695w1pczpq
7 Jun 21
FDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
9:13am
424B3
5gtv4h jzqi
3 Jun 21
Prospectus supplement
6:06am
424B3
6ohjdbc
3 Jun 21
Prospectus supplement
6:06am
6-K
c0k19kw0vnn6cvd
3 Jun 21
FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
6:03am
424B3
ioegs x1owp1
2 Jun 21
Prospectus supplement
10:10am
424B3
m4nykk9abv esg
2 Jun 21
Prospectus supplement
10:09am
424B3
cl24gj
2 Jun 21
Prospectus supplement
10:08am
6-K
d44iqt9pqpw4ms4mjv9
2 Jun 21
Amryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
9:02am
6-K
q62h57a50m s52e
5 May 21
Agreement and Plan of Merger
5:19pm
6-K
q0o305tc3cidj
5 May 21
Amryt Reports Record Q1 2021 Financial and Operating Results
9:40am
6-K
lwa97ro3
5 May 21
Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
8:45am
20-F
8amb3lu po
30 Apr 21
Annual report (foreign)
12:53pm
6-K
vog5kumh ojj0r03
31 Mar 21
Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada
7:00am
424B3
ujdx77jmlfn2fy4o07l
4 Mar 21
Prospectus supplement
8:38am
6-K
4muk51ocfa f3gku4s89
4 Mar 21
Amryt Announces Record FY 2020 Results
8:20am
6-K
leo gi6h2d
20 Jan 21
Amryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
6:30am
424B4
zm7xrq
14 Jan 21
Prospectus supplement with pricing info
9:30am
F-1/A
fojwetjgzb6ai
12 Jan 21
Registration statement (foreign) (amended)
12:00am
F-1
kajzbxo umc31ri6y2xr
8 Jan 21
Registration statement (foreign)
4:58pm
F-1
EX-5.1
hwuc7ho4ry00j8zkzsh
8 Jan 21
Registration statement (foreign)
4:58pm